Death of volunteer who took dose of Covaxin not related to vaccine or placebo, says Bharat Biotech
Representational image
The company says that at the time of enrolment, the 42-year-old volunteer in Bhopal had fulfilled all criteria to be accepted as participant in Phase III trial
The volunteer was reported to be healthy in all site follow up calls post seven days of dosing and no after-effects were observed/reported, says the firm
Share Via
Read Full Story
New Delhi: Hyderabad-based Bharat Biotech on Saturday said that the death of a 42-year-old volunteer from Bhopal in Madhya Pradesh who took a dose of ovaxin in the clinical trial of the Covid-19 vaccine was not related to the vaccine or placebo.
Days after participating in covid-19 vaccine trial, man dies in Bhopal
Premium
2 min read
Share Via
Read Full Story A 42-year-old volunteer from Bhopal in Madhya Pradesh died nearly ten days after he participated in the clinical trial for Covaxin held at a private hospital
Dr Rajesh Kapur, Vice Chancellor, People s Medical College and Hospital where the trial was conducted, told PTI that Deepak Marawi had participated in the Covaxin trial held on December 12, 2020.
TRENDING STORIESSee All
Premium
5 min read
Premium
2 min read
Premium
PPF vs NPS calculator: Key things to know if you want to invest ₹8,000 per month
2 min read
Representative image
BHOPAL: A 42-year-old man who had taken part in the trial of Covaxin, the indigenous coronavirus vaccine developed by Bharat Biotech, died nine days later in Bhopal, officials said.
While doctors suspect that poisoning could be the cause, Bharat Biotech said in a statement that preliminary reviews indicate that the death was unrelated to the vaccine trial.
Dr Rajesh Kapur, vice chancellor, People s Medical College and Hospital where the trial was conducted, told PTI that Deepak Marawi, the deceased, had participated in the Covaxin tria on December 12. He died nine days later.
Bharat Biotech said in a statement that Marawi had fulfilled all the inclusion and exclusion criteria to be accepted as a participant in the Phase III trial .
India will launch its COVID-19 vaccination drive from 16 January, with priority to be given to nearly three crore healthcare and frontline workers.
The decision, the government said on Saturday, was taken at a high-level meeting where Modi reviewed the status of COVID-19 and vaccine preparedness across states and union territories. After the detailed review, it was decided that in view of the forthcoming festivals including Lohri, Makar Sankranti, Pongal, Magh Bihu etc, the COVID-19 vaccination will start from 16th January 2021, it said.
After healthcare and frontline workers, priority will be given to those above 50 years of age and the under-50 population groups with co-morbidities, together numbering around 27 crore, a government statement said.
A 42-year-old man who had taken part in the trial of Covaxin, the indigenous coronavirus vaccine developed by Bharat Biotech, died nine days later in Bhopal, officials said. While doctors suspect that poisoning could be the cause, Bharat Biotech said in a statement that “preliminary reviews” indicate that the death was unrelated to the vaccine trial. To be clear, it is unknown if the man was administered the vaccine or placebo.